Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 12:39 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2857–2880 of 79,423 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 2 Clear all

Conditions: PCOS, Polycystic Ovary Syndrome
Interventions: Micronized progesterone, Placebo, Flutamide, Estradiol patch; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 30 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Osteoarthritis
Interventions: TDS-943 (topical diclofenac sodium 4% spray), celecoxib, placebo; Drug · Other
Lead sponsor: Mika Pharma GmbH; Industry
Eligibility: 40 Years and older
Enrollment: 650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 49
States / cities: Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 42 more

Conditions: Growth Disorder, Growth Hormone Deficiency in Children
Interventions: No treatment given; Other
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 4 Years to 13 Years
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 24
States / cities: Phoenix, Arizona • Centennial, Colorado • Wilmington, Delaware + 20 more

Conditions: Prostate Cancer
Interventions: Ozarelix, Goserelin; Drug
Lead sponsor: Spectrum Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 3
States / cities: Denver, Colorado • Dallas, Texas • San Antonio, Texas

Conditions: Healthy
Interventions: Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg, Benicar HCT® Tablets 40 mg/25 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Heart Failure, Hypertension
Interventions: PAL2, PHARM-PAL2; Behavioral · Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 364 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Depemokimab, Placebo; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 961 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 56
States / cities: Sheffield, Alabama • Aurora, Colorado • Brooksville, Florida + 48 more

Conditions: Multiple Sclerosis (MS)
Interventions: Ocrelizumab, rHuPH20; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 18
States / cities: Aurora, Colorado • Washington D.C., District of Columbia • Alexandria, Louisiana + 15 more

Conditions: Fontan Physiology, Frailty
Interventions: Home exercise program; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 19 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Alzheimer's Disease
Interventions: LY2811376, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 20 Years to 65 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Glendale, California

Conditions: Respiratory Papillomatosis
Interventions: INO-3107, CELLECTRA® 2000; Drug · Device
Lead sponsor: Inovio Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 11
States / cities: Phoenix, Arizona • Sacramento, California • Atlanta, Georgia + 7 more

Conditions: PARKINSON DISEASE (Disorder), Parkinson s Disease
Interventions: TMS; Device
Lead sponsor: San Francisco Neurology and Sleep Center; Other
Eligibility: 50 Years to 90 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hepatitis C
Interventions: GSK2485852 70 mg, GSK2485852 420 mg, placebo, GSK2485852 630 mg, GSK2485852 70 mg + Ritonavir 100mg, GSK2485852 210 mg +Ritonavir 100mg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 5
States / cities: Anaheim, California • Orlando, Florida • Lenexa, Kansas + 2 more

Conditions: Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type
Interventions: bifeprunox, Placebo; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 65 Years to 90 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 35
States / cities: Phoenix, Arizona • Carson, California • Long Beach, California + 28 more

Conditions: Women at Increased Risk for Developing Breast Carcinoma
Interventions: Mammography (CESM) and MRI; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years and older · Female only
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Arthritis, Gouty
Interventions: Indomethacin, Celecoxib; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 402 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 43
States / cities: Glendale, Arizona • Mesa, Arizona • Paradise Valley, Arizona + 37 more

Conditions: Gastric Cancer, Stomach Cancer
Interventions: Potentially curative surgery, Floxuridine (IP), Adjuvant Chemoradiation therapy; Procedure · Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2012
U.S. locations: 3
States / cities: New York, New York

Conditions: Mild Cognitive Impairment (MCI)
Interventions: AI-Supported Cognitive Rehabilitation; Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 65 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Pasadena, California

Conditions: Prostate Adenocarcinoma
Interventions: Lu-17-PSMA-617; Drug
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 18 Years and older · Male only
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Hackensack, New Jersey

Conditions: Central Centrifugal Cicatricial Alopecia, Lichen Planopilaris
Interventions: Delgocitinib; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Seasonal Allergic Conjunctivitis
Interventions: Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution, Ketotifen fumarate ophthalmic solution 0.035%, Brimonidine tartrate ophthalmic solution 0.025%, Experimental: Vehicle ophthalmic solution; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 6
States / cities: Louisville, Kentucky • Andover, Massachusetts • Goodlettsville, Tennessee + 3 more

Conditions: HIV Infections
Interventions: Sub C gp140 Vaccine, MF59C.1 Adjuvant; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 3
States / cities: Birmingham, Alabama • Nashville, Tennessee • Seattle, Washington

Conditions: Cytomegaloviral Infection, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions: Allogeneic Cytomegalovirus-Specific Cytotoxic T lymphocytes; Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Food Allergy in Children
Interventions: Food Allergy Mastery Program; Behavioral
Lead sponsor: Children's National Research Institute; Other
Eligibility: 10 Years to 14 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Search by objective public record fields.

Androgen Blockade and Progesterone Augmentation of Gonadotropin Secretion

Study Evaluating the Efficacy and Safety of Topical Diclofenac Spray in Osteoarthritis of the Knee: Trial II

Validation of Two Measures for Growth Hormone Deficiency in Children, the Treatment Related Impact Measure of Childhood Growth Hormone Deficiency (TRIM-CGHD) and the Treatment Burden Measure of Childhood Growth Hormone Deficiency (TB-CGHD)

International,Multi-Center,Open Label,Randomized Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot in Men With Prostate Cancer

Fasting Study of Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg and Benicar HCT® Tablets 40 mg/25 mg

Project 2: ACHIEVE- HF

Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)

A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis

Home Exercise And Resiliency Training (Heart) Club

A Safety Study of LY2811376 Single Doses in Healthy Subjects

INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP)

Effects of Accelerated rTMS On Motor and Cognitive Function in Parkinson's Disease

A First Time in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Single and Repeat Doses of GSK2485852 in Chronically Infected Hepatitis C Subjects

Treatment of Elderly Subjects With Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type

Comparison of Contrast Enhanced Mammography to Breast MRI in Screening Patients at Increased Risk for Breast Cancer

Celebrex In Acute Gouty Arthritis Study

Adjuvant Intraperitoneal Floxuridine Added to Chemoradiation for Fully Resected Advanced Stomach Cancer

AI-Supported Cognitive Rehabilitation for Older Adults With Mild Cognitive Impairment

Neoadjuvant Lu-177-PSMA-617 in Patients With High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy

Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilaris

Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic Conjunctivitis

Evaluating the Safety and Immune Response to an HIV Vaccine in Healthy, HIV-Uninfected Adults Who Have Participated in Previous HIV Vaccine Clinical Trials and in Adults Who Have Not Participated in Previous HIV Vaccine Clinical Trials

Donor Cytomegalovirus-Specific Cytotoxic T-Lymphocytes in Treating Patients With a Persistent Cytomegalovirus Infection

Evaluation of The Food Allergy Mastery Program